Cited by 5,198PARP inhibition in cancer therapyDNA Repair MechanismsBRCA gene mutations in cancer

The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.

Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase

Open access

Bryant, Helen E., Schultz, Niklas, Thomas, Huw D., Parker, Kayan M., Flower, Dan, Lopez, Elena, Kyle, Suzanne, Meuth, Mark, Curtin, Nicola J., Helleday, Thomas·2005·Nature

DOI 10.1038/nature03443

Open this paper in CoChat — free account

Abstract

Poly(ADP-ribose) polymerase (PARP1) facilitates DNA repair by binding to DNA breaks and attracting DNA repair proteins to the site of damage. Nevertheless, PARP1-/- mice are viable, fertile and do not develop early onset tumours. Here, we show that PARP inhibitors trigger gamma-H2AX and RAD51 foci formation. We propose that, in the absence of PARP1, spontaneous single-strand breaks collapse replication forks and trigger homologous recombination for repair. Furthermore, we show that BRCA2-deficient cells, as a result of their deficiency in homologous recombination, are acutely sensitive to PARP inhibitors, presumably because resultant collapsed replication forks are no longer repaired. Thus, PARP1 activity is essential in homologous recombination-deficient BRCA2 mutant cells. We exploit this requirement in order to kill BRCA2-deficient tumours by PARP inhibition alone. Treatment with PARP inhibitors is likely to be highly tumour specific, because only the tumours (which are BRCA2-/-) in BRCA2+/- patients are defective in homologous recombination. The use of an inhibitor of a DNA repair enzyme alone to selectively kill a tumour, in the absence of an exogenous DNA-damaging agent, represents a new concept in cancer treatment.

Integrity signals

Registry

Crossref · 10.1038/nature03443

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683
Instability and decay of the primary structure of DNA
Lindahl, T. (1993) · Nature · doi:10.1038/362709a0 · Cited by 5,679
A critical role for histone H2AX in recruitment of repair factors to nuclear foci after DNA damage
Paull, T. T., Rogakou, E. P., Yamazaki, V., Kirchgessner, C. U., Gellert, M., & Bonner, W. M. (2000) · Current Biology · doi:10.1016/s0960-9822(00)00610-2 · Cited by 2,098
Poly(ADP-ribosyl)ation reactions in the regulation of nuclear functions
D’Amours, D., Desnoyers, S., D’Silva, I., & Poirier, G. G. (1999) · Biochemical Journal · doi:10.1042/bj3420249 · Cited by 1,819
Cancer Susceptibility and the Functions of BRCA1 and BRCA2
Venkitaraman, A. R. (2002) · Cell · doi:10.1016/s0092-8674(02)00615-3 · Cited by 1,713
Requirement of poly(ADP-ribose) polymerase in recovery from DNA damage in mice and in cells
Murcia, J. M., Niedergang, C., Trucco, C., Ricoul, M., Dutrillaux, B., Mark, M. P., Oliver, F. J., Masson, M., Dierich, A., LeMeur, M., et al. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.14.7303 · Cited by 1,058
A requirement for PARP-1 for the assembly or stability of XRCC1 nuclear foci at sites of oxidative DNA damage
El‐Khamisy, S. F. (2003) · Nucleic Acids Research · doi:10.1093/nar/gkg761 · Cited by 689
Functional interaction between PARP‐1 and PARP‐2 in chromosome stability and embryonic development in mouse
Murcia, J. M., Ricoul, M., Tartier, L., Niedergang, C., Huber, A., Dantzer, F., Schreiber, V., Amé, J., Dierich, A., LeMeur, M., et al. (2003) · The EMBO Journal · doi:10.1093/emboj/cdg206 · Cited by 629
Post-translational modification of poly(ADP-ribose) polymerase induced by DNA strand breaks
Lindahl, T. L., Satoh, M. S., Poirier, G. G., & Klungland, A. (1995) · Trends in Biochemical Sciences · doi:10.1016/s0968-0004(00)89089-1 · Cited by 611
PARP is important for genomic stability but dispensable in apoptosisPreprint
Wang, Z., Stingl, L., Morrison, C. G., Jantsch, M. F., Łoś, M., Schulze‐Osthoff, K., & Wagner, E. F. (1997) · Genes & Development · doi:10.1101/gad.11.18.2347 · Cited by 557

Show all 26 references

Sorted by citations

Items 901–1,000 of 1,021

Simultaneous Targeting of PARP1 and RAD52 Triggers Dual Synthetic Lethality in BRCA-Deficient Tumor Cells
Sullivan-Reed, K., Bolton-Gillespie, E., Dasgupta, Y., Langer, S. K., Siciliano, M., Nieborowska-Skorska, M., Hanamshet, K., Belyaeva, E. A., Bernhardy, A. J., Lee, J. W., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.05.034 · Cited by 96
Molecular profile of BRCA-mutated biliary tract cancers
Spizzo, G., Puccini, A., Xiu, J., Goldberg, R. M., Grothey, A. F., Shields, A. F., Arora, S. P., Khushman, M. M., Salem, M. E., Battaglin, F., et al. (2020) · ESMO Open · doi:10.1136/esmoopen-2020-000682 · Cited by 96
BET proteins: Biological functions and therapeutic interventions
Guo, J., Zheng, Q., & Peng, Y. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108354 · Cited by 96
Mechanisms of PARP-Inhibitor-Resistance in BRCA-Mutated Breast Cancer and New Therapeutic Approaches
Dilmaç, S., & Özpolat, B. (2023) · Cancers · doi:10.3390/cancers15143642 · Cited by 96
Interfaces between cellular responses to DNA damage and cancer immunotherapyPreprint
Pilger, D., Seymour, L. W., & Jackson, S. P. (2021) · Genes & Development · doi:10.1101/gad.348314.121 · Cited by 96
The PARP inhibitor olaparib enhances the sensitivity of Ewing sarcoma to trabectedin
Ordóñez, J. L., Amaral, A. T., Carcaboso, A. M., Herrero‐Martín, D., García-Macías, M. D. C., Sevillano, V., Alonso, D., Pascual‐Pasto, G., San‐Segundo, L., Vilà-Ubach, M., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.4303 · Cited by 95
Neurofibromin and suppression of tumorigenesis: beyond the GAP
Mo, J., Moye, S. L., McKay, R. M., & Le, L. Q. (2022) · Oncogene · doi:10.1038/s41388-021-02156-y · Cited by 95
Epithelial Ovarian Cancer: Providing Evidence of Predisposition Genes
Shah, S., Cheung, A., Kutka, M., Sheriff, M., & Boussios, S. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph19138113 · Cited by 95
Synthetic lethal targeting of DNA double‐strand break repair deficient cells by human apurinic/apyrimidinic endonuclease inhibitors
Sultana, R., McNeill, D. R., Abbotts, R., Mohammed, M. Z., Zdzienicka, M. Z., Qutob, H. M. H., Seedhouse, C., Laughton, C. A., Fischer, P. M., Patel, P. M., et al. (2012) · International Journal of Cancer · doi:10.1002/ijc.27512 · Cited by 95
The properties of tumor-initiating cells from a hepatocellular carcinoma patient's primary and recurrent tumor
Xu, X.-L., Xing, B.-C., Han, H.-B., Zhao, W., Hu, M.-H., Xu, Z.-L., Li, W., Xie, Y., Gu, J., Wang, Y., et al. (2009) · Carcinogenesis · doi:10.1093/carcin/bgp232 · Cited by 95
DNA double-strand break signaling and human disorders
Bohgaki, T., Bohgaki, M., & Hakem, R. (2010) · Genome Integrity · doi:10.1186/2041-9414-1-15 · Cited by 95
Breast Cancer Proteins PALB2 and BRCA2 Stimulate Polymerase η in Recombination-Associated DNA Synthesis at Blocked Replication Forks
Buisson, R., Joshi, N., Pauty, J., Maity, R., Zhao, W., Coulombe, Y., Sung, P., & Masson, J. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.01.009 · Cited by 95
A negative genetic interaction map in isogenic cancer cell lines reveals cancer cell vulnerabilities
Vizeacoumar, F. J., Arnold, R. R., Vizeacoumar, F. S., Chandrashekhar, M., Buzina, A., Young, J. T. F., Kwan, J., Sayad, A., Mero, P., Lawo, S., et al. (2013) · Molecular Systems Biology · doi:10.1038/msb.2013.54 · Cited by 94
PARP1 changes from three-dimensional DNA damage searching to one-dimensional diffusion after auto-PARylation or in the presence of APE1
Liu, L., Kong, M., Gassman, N. R., Freudenthal, B., Prasad, R., Zhen, S., Watkins, S. C., Wilson, S. H., & Houten, B. V. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkx1047 · Cited by 94
Developing Targeted Therapies That Exploit Aberrant Histone Ubiquitination in Cancer
Jeusset, L. M., & McManus, K. J. (2019) · Cells · doi:10.3390/cells8020165 · Cited by 95
AMG 193, a Clinical Stage MTA-Cooperative PRMT5 Inhibitor, Drives Antitumor Activity Preclinically and in Patients with MTAP-Deleted Cancers
Belmontes, B., Slemmons, K. K., Su, C., Liu, S., Policheni, A. N., Moriguchi, J., Tan, H. L. E., Xie, F., Aiello, D. A., Yang, Y., et al. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-24-0887 · Cited by 99
DNA Repair Biomarker Profiling of Head and Neck Cancer: Ku80 Expression Predicts Locoregional Failure and Death following Radiotherapy
Moeller, B. J., Yordy, J. S., Williams, M. D., Giri, U. P., Raju, U., Molkentine, D. P., Byers, L. A., Heymach, J. V., Story, M. D., Lee, J. J., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2641 · Cited by 94
The potential for poly (ADP-ribose) polymerase inhibitors in cancer therapy
Javle, M. M., & Curtin, N. J. (2011) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834011417039 · Cited by 94
Self-citation
Inhibition of poly(ADP-ribose) glycohydrolase (PARG) specifically kills BRCA2-deficient tumor cells
Fathers, C., Drayton, R. M., Solovieva, S. E., & Bryant, H. E. (2012) · Cell Cycle · doi:10.4161/cc.11.5.19482 · Cited by 94
Self-citation
Synergistic Loss of Prostate Cancer Cell Viability by Coinhibition of HDAC and PARP
Chao, O. S., & Goodman, O. B. (2014) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-14-0173 · Cited by 94
Vulnerabilities of PTEN – TP53 -Deficient Prostate Cancers to Compound PARP–PI3K Inhibition
González‐Billalabeitia, E., Seitzer, N., Song, S. J., Song, M. S., Patnaik, A., Liu, X., Epping, M. T., Papa, A., Hobbs, R. M., Chen, M., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0230 · Cited by 95
The PARP Inhibitor AZD2461 Provides Insights into the Role of PARP3 Inhibition for Both Synthetic Lethality and Tolerability with Chemotherapy in Preclinical Models
O’Connor, L. O., Rulten, S. L., Cranston, A. N., Odedra, R., Brown, H., Jaspers, J. E., Jones, L., Knights, C., Evers, B., Ting, A. K. T., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-3240 · Cited by 93
Discovery of Pamiparib (BGB-290), a Potent and Selective Poly (ADP-ribose) Polymerase (PARP) Inhibitor in Clinical Development
Wang, H., Ren, B. X., Liu, Y., Jiang, B., Guo, Y., Wei, M., Luo, L., Kuang, X., Qiu, M., Lv, L., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01346 · Cited by 93
DNA–Protein Crosslinks and Their Resolution
Weickert, P., & Stingele, J. (2022) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-032620-105820 · Cited by 96
Poly-ADP-ribose polymerase: Machinery for nuclear processes
Thomas, C. J., & Tulin, A. V. (2013) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2013.04.001 · Cited by 93
BRCAness: Finding the Achilles Heel in Ovarian Cancer
Rigakos, G., & Razis, E. D. (2012) · The Oncologist · doi:10.1634/theoncologist.2012-0028 · Cited by 93
Acquired Resistance to Combination Treatment with Temozolomide and ABT-888 Is Mediated by Both Base Excision Repair and Homologous Recombination DNA Repair Pathways
Liu, X., Han, E. K.-H., Anderson, M. G., Shi, Y., Semizarov, D., Wang, G., McGonigal, T. P., Roberts, L., Lasko, L. M., Palma, J. P., et al. (2009) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-09-0299 · Cited by 93
Misregulation of DNA damage repair pathways in HPV-positive head and neck squamous cell carcinoma contributes to cellular radiosensitivity
Nickson, C. M., Moori, P. L., Carter, R. J., Rubbi, C. P., & Parsons, J. L. (2017) · Oncotarget · doi:10.18632/oncotarget.16265 · Cited by 93
Beyond PARP—POLθ as an anticancer target
Higgins, G. S., & Boulton, S. J. (2018) · Science · doi:10.1126/science.aar5149 · Cited by 93
Mapping molecular subtype specific alterations in breast cancer brain metastases identifies clinically relevant vulnerabilities
Cosgrove, N. S., Varešlija, D., Keelan, S., Elangovan, A., Atkinson, J. M., Cocchiglia, S., Bane, F. T., Singh, V., Furney, S. J., Hu, C., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-27987-5 · Cited by 92
DNA Repair Targeting and Radiotherapy: A Focus on the Therapeutic Ratio
Thoms, J., & Bristow, R. G. (2010) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2010.06.003 · Cited by 92
Differential anti-proliferative activities of poly(ADP-ribose) polymerase (PARP) inhibitors in triple-negative breast cancer cells
Chuang, H.-C., Kapuriya, N. P., Kulp, S. K., Chen, C., & Shapiro, C. L. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-012-2106-5 · Cited by 91
A fine-scale dissection of the DNA double-strand break repair machinery and its implications for breast cancer therapy
Liu, C., Srihari, S., Cao, K. L., Chenevix‐Trench, G., Simpson, P. T., Ragan, M. A., & Khanna, K. K. (2014) · Nucleic Acids Research · doi:10.1093/nar/gku284 · Cited by 91
BRCA2 functions: from DNA repair to replication fork stabilization
Fradet‐Turcotte, A., Sitz, J., Grapton, D., & Orthwein, A. (2016) · Endocrine Related Cancer · doi:10.1530/erc-16-0297 · Cited by 91
DNA damage response and cancer therapeutics through the lens of the Fanconi Anemia DNA repair pathway
Bhattacharjee, S., & Nandi, S. (2017) · Cell Communication and Signaling · doi:10.1186/s12964-017-0195-9 · Cited by 91
Cooperation of the ATM and Fanconi Anemia/BRCA Pathways in Double-Strand Break End Resection
Cai, M., Dunn, C. E., Chen, W., Kochupurakkal, B. S., Nguyen, H. Q., Moreau, L. A., Shapiro, G. I., Parmar, K., Kozono, D., & D’Andrea, A. D. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.01.052 · Cited by 91
Poly(ADP-Ribose)Polymerase (PARP) Inhibitors and Radiation Therapy
Jannetti, S. A., Zeglis, B. M., Zalutsky, M. R., & Reiner, T. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00170 · Cited by 91
History of DNA Helicases
Brosh, R. M., & Matson, S. W. (2020) · Genes · doi:10.3390/genes11030255 · Cited by 93
Resistance to DNA repair inhibitors in cancer
Baxter, J. S., Zatreanu, D. A., Pettitt, S. J., & Lord, C. J. (2022) · Molecular Oncology · doi:10.1002/1878-0261.13224 · Cited by 91
Rapid regulation of telomere length is mediated by poly(ADP-ribose) polymerase-1
Beneke, S., Cohausz, O., Malanga, M., Boukamp, P., Althaus, F., & Bürkle, A. (2008) · Nucleic Acids Research · doi:10.1093/nar/gkn615 · Cited by 91
Radiosensitization by PARP Inhibition in DNA Repair Proficient and Deficient Tumor Cells: Proliferative Recovery in Senescent Cells
Alotaibi, M. R., Sharma, K., Saleh, T., Povirk, L. F., Hendrickson, E. A., & Gewirtz, D. A. (2016) · Radiation Research · doi:10.1667/rr14202.1 · Cited by 91
Efficacy of ATR inhibitors as single agents in Ewing sarcoma
Nieto-Soler, M., Morgado-Palacin, I., Lafarga, V., Lecona, E., Murga, M., Callén, E., Azorín, D., Alonso, J., Lopez-Contreras, A. J., Nussenzweig, A., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.11643 · Cited by 91
Achieving Precision Death with Cell-Cycle Inhibitors that Target DNA Replication and Repair
Bence, A. K., McNeely, S., & Beckmann, R. P. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0083 · Cited by 91
Synthetic Lethality and Cancer – Penetrance as the Major Barrier
Ryan, C. J., Bajrami, I., & Lord, C. J. (2018) · Trends in cancer · doi:10.1016/j.trecan.2018.08.003 · Cited by 91
Synthetic Lethal Vulnerabilities in KRAS-Mutant Cancers
Aguirre, A. J., & Hahn, W. C. (2018) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a031518 · Cited by 90
Deubiquitylating Enzymes and DNA Damage Response Pathways
Jacq, X., Kemp, M. I., Martin, N. M. B., & Jackson, S. P. (2013) · Cell Biochemistry and Biophysics · doi:10.1007/s12013-013-9635-3 · Cited by 90
Increased oxidative stress mediates the antitumor effect of PARP inhibition in ovarian cancer
Hou, D., Liu, Z., Xu, X., Liu, Q., Zhang, X., Kong, B., Wei, J., Gong, Y., & Shao, C. (2018) · Redox Biology · doi:10.1016/j.redox.2018.03.016 · Cited by 90
HPF1 remodels the active site of PARP1 to enable the serine ADP-ribosylation of histones
Sun, F.-H., Zhao, P., Zhang, N., Kong, L., Wong, C. C. L., & Yun, C. (2021) · Nature Communications · doi:10.1038/s41467-021-21302-4 · Cited by 90
Revolutionizing DNA repair research and cancer therapy with CRISPR–Cas screens
Awwad, S. W., Serrano-Benítez, A., Thomas, J. C., Gupta, V., & Jackson, S. P. (2023) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-022-00571-x · Cited by 93
The H2B ubiquitin ligase RNF40 cooperates with SUPT16H to induce dynamic changes in chromatin structure during DNA double-strand break repair
Kari, V., Shchebet, A., Neumann, H., & Johnsen, S. A. (2011) · Cell Cycle · doi:10.4161/cc.10.20.17769 · Cited by 90
Design, Synthesis, and Biological Evaluation of a Series of Benzo[de][1,7]naphthyridin-7(8H)-ones Bearing a Functionalized Longer Chain Appendage as Novel PARP1 Inhibitors
Ye, N., Chen, C.-H., Chen, T., Song, Z., He, J., Huan, X., Song, S.-S., Liu, Q., Chen, Y., Ding, J., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm301825t · Cited by 90
Homologous recombination and maintenance of genome integrity: Cancer and aging through the prism of human RecQ helicases
Ouyang, K. J., Woo, L. L., & Ellis, N. A. (2008) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2008.03.003 · Cited by 90
Perspective on the Pipeline of Drugs Being Developed with Modulation of DNA Damage as a Target
Plummer, R. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0984 · Cited by 90
TOPBP1 regulates RAD51 phosphorylation and chromatin loading and determines PARP inhibitor sensitivity
Moudrý, P., Watanabe, K., Wolanin, K., Bártková, J., Wassing, I. E., Watanabe, S., Strauss, R., Pedersen, R. T., Oestergaard, V. H., Lisby, M., et al. (2016) · The Journal of Cell Biology · doi:10.1083/jcb.201507042 · Cited by 90
Inhibition of Thioredoxin/Thioredoxin Reductase Induces Synthetic Lethality in Lung Cancers with Compromised Glutathione Homeostasis
Yan, X., Zhang, X., Wang, L., Zhang, R., Pu, X., Wu, S., Li, L., Tong, P., Wang, J., Meng, Q. H., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-1938 · Cited by 90
Phthalazinones 2: Optimisation and synthesis of novel potent inhibitors of poly(ADP-ribose)polymerase
Cockcroft, X. F., Dillon, K. J., Dixon, L., Drzewiecki, J., Kerrigan, F., Loh, V. M. J., Martin, N. M. B., Menear, K. A., & Smith, G. C. M. (2005) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2005.10.081 · Cited by 90
Mismatch repair deficiency in ovarian cancer — Molecular characteristics and clinical implications
Xiao, X., Melton, D. W., & Gourley, C. (2014) · Gynecologic Oncology · doi:10.1016/j.ygyno.2013.12.003 · Cited by 89
BRCA mutational status shapes the stromal microenvironment of pancreatic cancer linking clusterin expression in cancer associated fibroblasts with HSF1 signaling
Shaashua, L., Ben-Shmuel, A., Pevsner-Fischer, M., Friedman, G., Levi-Galibov, O., Nandakumar, S., Barki, D., Nevo, R., Brown, L. E., Zhang, W., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-34081-3 · Cited by 79
Self-citation
An Evolutionarily Conserved Synthetic Lethal Interaction Network Identifies FEN1 as a Broad-Spectrum Target for Anticancer Therapeutic Development
van Pel, D. M., Barrett, I. J., Shimizu, Y., Sajesh, B. V., Guppy, B. J., Pfeifer, T., McManus, K. J., & Hieter, P. (2013) · PLoS Genetics · doi:10.1371/journal.pgen.1003254 · Cited by 89
Cancer treatment according to BRCA1 and BRCA2 mutations
Maxwell, K. N., & Domchek, S. M. (2012) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2012.123 · Cited by 89
BRCA1 loss activates cathepsin L–mediated degradation of 53BP1 in breast cancer cells
Grotsky, D. A., González-Suárez, I., Novell, A., Neumann, M. A., Yaddanapudi, S. C., Croke, M., Martínez‐Alonso, M., Redwood, A. B., Ortega‐Martínez, S., Feng, Z., et al. (2013) · The Journal of Cell Biology · doi:10.1083/jcb.201204053 · Cited by 89
Activation of the PI3K/mTOR Pathway following PARP Inhibition in Small Cell Lung Cancer
Cardnell, R. J., Feng, Y., Mukherjee, S., Diao, L., Tong, P., Stewart, C. A., Masrorpour, F., Fan, Y.-H., Nilsson, M. B., Shen, Y., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0152584 · Cited by 89
VCP inhibitors induce endoplasmic reticulum stress, cause cell cycle arrest, trigger caspase‐mediated cell death and synergistically kill ovarian cancer cells in combination with Salubrinal
Bastola, P., Neums, L., Schoenen, F. J., & CHIEN, J. R. (2016) · Molecular Oncology · doi:10.1016/j.molonc.2016.09.005 · Cited by 89
The PARP inhibitor olaparib potentiates the effect of the DNA damaging agent doxorubicin in osteosarcoma
Park, H. J., Bae, J. S., Kim, K. M., Moon, Y. J., Park, S., Ha, S. H., Hussein, U. K., Zhang, Z., Park, H. S., Park, B., et al. (2018) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-018-0772-9 · Cited by 89
Design, synthesis, and biological evaluation of quinazolin-4(3H)-one derivatives co-targeting poly(ADP-ribose) polymerase-1 and bromodomain containing protein 4 for breast cancer therapy
Chang, X., Sun, D., Shi, D., Wang, G., Chen, Y., Zhang, K., Tan, H., Liu, J., Liu, B., & Ouyang, L. (2020) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2020.06.003 · Cited by 89
Micropeptide PACMP inhibition elicits synthetic lethal effects by decreasing CtIP and poly(ADP-ribosyl)ation
Zhang, C., Zhou, B. O., Gu, F., Liu, H., Wu, H., Yao, F., Zheng, H., Fu, H. Q., Chong, W., Cai, S., et al. (2022) · Molecular Cell · doi:10.1016/j.molcel.2022.01.020 · Cited by 89
Poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer
Tattersall, A., Ryan, N. A. J., Wiggans, A. J., Rogozińska, E., & Morrison, J. (2022) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007929.pub4 · Cited by 89
PARP1 roles in DNA repair and DNA replication: The basi(c)s of PARP inhibitor efficacy and resistance
Kanev, P.-B., Atemin, A., Stoynov, S., & Aleksandrov, R. (2023) · Seminars in Oncology · doi:10.1053/j.seminoncol.2023.08.001 · Cited by 89
Longitudinal profiling identifies co-occurring BRCA1/2 reversions, TP53BP1, RIF1 and PAXIP1 mutations in PARP inhibitor-resistant advanced breast cancer
Harvey-Jones, E. J., Raghunandan, M., Robbez‐Masson, L., Magraner-Pardo, L., Alaguthurai, T., Yablonovitch, A. L., Yen, J. L., Xiao, H. F., Brough, R., Frankum, J. R., et al. (2024) · Annals of Oncology · doi:10.1016/j.annonc.2024.01.003 · Cited by 89
PARP inhibitors for anticancer therapy
Curtin, N. J. (2014) · Biochemical Society Transactions · doi:10.1042/bst20130187 · Cited by 89
Self-citation
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial
Gelmon, K. A. (2011) · Breast Diseases A Year Book Quarterly · doi:10.1016/j.breastdis.2011.03.043 · Cited by 89
The emerging roles of CDK12 in tumorigenesis
Paculová, H., & Kohoutek, J. (2017) · Cell Division · doi:10.1186/s13008-017-0033-x · Cited by 89
Olaparib modulates DNA repair efficiency, sensitizes cervical cancer cells to cisplatin and exhibits anti-metastatic property
Prasad, C. B., Prasad, S. B., Yadav, S. S., Pandey, L. K., Singh, S., Pradhan, S., & Narayan, G. (2017) · Scientific Reports · doi:10.1038/s41598-017-13232-3 · Cited by 84
Development of Dual Inhibitors Targeting Epidermal Growth Factor Receptor in Cancer Therapy
Tan, L., Zhang, J., Wang, Y., Wang, X., Wang, Y., Zhang, Z., Shuai, W., Wang, G., Chen, J., Wang, C., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01714 · Cited by 88
DNA damage accumulation and repair defects in acute myeloid leukemia: implications for pathogenesis, disease progression, and chemotherapy resistance
Esposito, M. T., & So, C. W. E. (2014) · Chromosoma · doi:10.1007/s00412-014-0482-9 · Cited by 88
Choices have consequences: the nexus between DNA repair pathways and genomic instability in cancer
Bhattacharjee, S., & Nandi, S. (2016) · Clinical and Translational Medicine · doi:10.1186/s40169-016-0128-z · Cited by 88
A Role for Mitochondrial Translation in Promotion of Viability in K-Ras Mutant Cells
Martin, T. D., Cook, D. R., Choi, M. Y., Li, M. Z., Haigis, K. M., & Elledge, S. J. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.06.061 · Cited by 88
LMO2 Confers Synthetic Lethality to PARP Inhibition in DLBCL
Parvin, S., Ramírez-Labrada, A., Aumann, S., Lu, X., Weich, N., Santiago, G. E., Cortizas, E. M., Sharabi, E., Zhang, Y., Sánchez-Garcı́a, I., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.07.007 · Cited by 88
Talazoparib in Patients with a Germline BRCA -Mutated Advanced Breast Cancer: Detailed Safety Analyses from the Phase III EMBRACA Trial
Hurvitz, S. A., Gonçalvès, A., Rugo, H. S., Lee, K.-H., Fehrenbacher, L., Mina, L. A., Diab, S., Blum, J. L., Chakrabarti, J., Elmeliegy, M. A., et al. (2019) · The Oncologist · doi:10.1634/theoncologist.2019-0493 · Cited by 88
New and Emerging Systemic Therapeutic Options for Advanced Cholangiocarcinoma
Massironi, S., Pilla, L., Elvevi, A., Longarini, R., Rossi, R. E., Bidoli, P., & Invernizzi, P. (2020) · Cells · doi:10.3390/cells9030688 · Cited by 88
Clinical PARP inhibitors do not abrogate PARP1 exchange at DNA damage sites in vivo
Shao, Z., Lee, B. J., Rouleau-Turcotte, É., Langelier, M.-F., Lin, X., Estes, V. M., Pascal, J. M., & Zha, S. (2020) · Nucleic Acids Research · doi:10.1093/nar/gkaa718 · Cited by 88
Discovery of SK-575 as a Highly Potent and Efficacious Proteolysis-Targeting Chimera Degrader of PARP1 for Treating Cancers
Cao, C.-G., Yang, J., Chen, Y. X., Zhou, P., Wang, Y., Du, W., Zhao, L., & Chen, Y. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00821 · Cited by 88
Breast Cancer Heterogeneity and Response to Novel Therapeutics
Baliu‐Piqué, M., Pandiella, A., & Ocaña, A. (2020) · Cancers · doi:10.3390/cancers12113271 · Cited by 88
The Oncogenic Helicase ALC1 Regulates PARP Inhibitor Potency by Trapping PARP2 at DNA Breaks
Blessing, C., Mandemaker, I. K., Gonzalez-Leal, C., Preißer, J., Schomburg, A., & Ladurner, A. G. (2020) · Molecular Cell · doi:10.1016/j.molcel.2020.10.009 · Cited by 88
Hesperidin protects against the chlorpyrifos‐induced chronic hepato‐renal toxicity in rats associated with oxidative stress, inflammation, apoptosis, autophagy, and up‐regulation of PARP‐1 / VEGF
Küçükler, S., Çomaklı, S., Özdemir, S., Çağlayan, C., & Kandemır, F. M. (2021) · Environmental Toxicology · doi:10.1002/tox.23156 · Cited by 88
The future of antibiotics begins with discovering new combinations
Zhu, M., Tse, M. W., Weller, J., Chen, J., & Blainey, P. C. (2021) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.14649 · Cited by 88
PARP inhibitors in cancer therapy: Two modes of attack on the cancer cell widening the clinical applications
Drew, Y., & Plummer, R. (2009) · Drug Resistance Updates · doi:10.1016/j.drup.2009.10.001 · Cited by 88
Two sides of the Myc-induced DNA damage response: from tumor suppression to tumor maintenance
Campaner, S., & Amati, B. B. (2012) · Cell Division · doi:10.1186/1747-1028-7-6 · Cited by 88
E7449: A dual inhibitor of PARP1/2 and tankyrase1/2 inhibits growth of DNA repair deficient tumors and antagonizes Wnt signaling
McGonigle, S., Chen, Z., Wu, J., Chang, P., Kolber, D. L., Ackermann, K. E., Twine, N. C., Shie, J., Miu, J. T., Huang, K., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.5846 · Cited by 88
Combined Radiation Therapy and Immune Checkpoint Blockade Therapy for Breast Cancer
Hu, Z. I., Ho, A. Y., & McArthur, H. L. (2017) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2017.05.029 · Cited by 88
The DNA damage response pathway as a land of therapeutic opportunities for colorectal cancer
Mauri, G., Arena, S., Siena, S., Bardelli, A., & Bianchi, A. S. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.05.027 · Cited by 87
Alternative Non-Homologous End-Joining: Error-Prone DNA Repair as Cancer’s Achilles’ Heel
Caracciolo, D., Riillo, C., Martino, M. T. D., Tagliaferri, P., & Tassone, P. (2021) · Cancers · doi:10.3390/cancers13061392 · Cited by 87
The telomeric PARP, tankyrases, as targets for cancer therapy
Seimiya, H. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6602951 · Cited by 87
The role of PARP1 in the DNA damage response and its application in tumor therapy
Wang, Z., Wang, F., Tang, T.-S., & Guo, C. (2012) · Frontiers of Medicine · doi:10.1007/s11684-012-0197-3 · Cited by 87
Premature mitotic entry induced by ATR inhibition potentiates olaparib inhibition-mediated genomic instability, inflammatory signaling, and cytotoxicity in BRCA2-deficient cancer cells
Schoonen, P. M., Kok, Y. P., Wierenga, E., Bakker, B., Foijer, F., Spierings, D. C. J., & van Vugt, M. A. T. M. (2019) · Molecular Oncology · doi:10.1002/1878-0261.12573 · Cited by 81
The Validation and Clinical Implementation of BRCAplus: A Comprehensive High-Risk Breast Cancer Diagnostic Assay
Chong, H. K., Wang, T., Lu, H., Seidler, S., Lu, H. Y., Keiles, S. B., Chao, E., Stuenkel, A. J., Li, X., & Elliott, A. M. (2014) · PLoS ONE · doi:10.1371/journal.pone.0097408 · Cited by 86
HIF-independent synthetic lethality between CDK4/6 inhibition and VHL loss across species
Nicholson, H. E., Tariq, Z., Housden, B. E., Jennings, R. B., Stransky, L. A., Perrimon, N., Signoretti, S., Harris, I. S., Endress, J. E., & Kaelin, W. G. (2019) · Science Signaling · doi:10.1126/scisignal.aay0482 · Cited by 86
Methylated DNA Causes a Physical Block to Replication Forks Independently of Damage Signalling, O6-Methylguanine or DNA Single-Strand Breaks and Results in DNA Damage
Groth, P., Ausländer, S., Majumder, M. M., Schultz, N., Johansson, F., Petermann, E., & Helleday, T. (2010) · Journal of Molecular Biology · doi:10.1016/j.jmb.2010.07.010 · Cited by 86
Self-citation
Targeting the DNA damage response for cancer therapy
Powell, S. N., & Bindra, R. S. (2009) · DNA repair · doi:10.1016/j.dnarep.2009.04.011 · Cited by 86
Small interfering RNA library screen identified polo-like kinase-1 (PLK1) as a potential therapeutic target for breast cancer that uniquely eliminates tumor-initiating cells
Hu, K., Law, J. H., Fotovati, A., & Dunn, S. E. (2012) · Breast Cancer Research · doi:10.1186/bcr3107 · Cited by 86

Authors: Bryant, H. E., Schultz, N., Thomas, H. D., Parker, K. M., Flower, D., Lopez, E., Kyle, S., Meuth, M., Curtin, N. J., & Helleday, T.
Affiliations: University of Sheffield (GB)
Stockholm University (SE)
Newcastle University (GB)
Corresponding author: Helleday, Thomas
ORCID: Bryant, Helen E.
Thomas, Huw D.
Curtin, Nicola J.
Helleday, Thomas
Venue: Nature
Publisher: Springer Science and Business Media LLC
Published: 2005-04-14
Volume: 434
Issue: 7035
Pages: 913-917
ISSN: 0028-0836 (ISSN-L)
1476-4687
DOI: 10.1038/nature03443
OpenAlex: W2009007206
Cited by: 5,198
References: 26
Citations by year: 2026: 213 · 2025: 256 · 2024: 286 · 2023: 355 · 2022: 355 · 2021: 396 · 2020: 388 · 2019: 282 · 2018: 290 · 2017: 273 · 2016: 265 · 2015: 230 · 2014: 243 · 2013: 223 · 2012: 213
FWCI: 56.59
Type: journal article
Language: en
Update notices: erratum (2007-05-17)
Open access: green
doi.org
Licence: www.springer.com/tdm (tdm)
www.springer.com/tdm (vor)
Locations: Nature (publishedVersion)
PubMed (publishedVersion)
RePEc: Research Papers in Economics (submittedVersion)
Newcastle University ePrints (Newcastle Univesity)
Funders: National Cancer Institute (F31CA260794)
Topics: Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › DNA Repair Mechanisms
Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
Keywords: PARP inhibitors, BRCA2 deficiency, homologous recombination, synthetic lethality, breast cancer, PARP1, DNA repair, replication fork collapse, single-strand breaks, γH2AX foci, RAD51 foci, base excision repair
MeSH terms: Poly(ADP-ribose) Polymerase Inhibitors, Animals, Antineoplastic Agents, Benzodiazepines, DNA Damage, DNA Repair, DNA Replication, Mice, Nude, Neoplasms, Poly(ADP-ribose) Polymerases, Xenograft Model Antitumor Assays, Genes, BRCA2, BRCA2 Protein, Cell Line, Tumor, Mice, Azulenes

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks